Immutep Receives Australian R&D Tax Incentive
14. November 2022 08:00 ET
|
Immutep Limited
Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce...
Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting
10. November 2022 11:10 ET
|
Immutep Limited
Media Release Overall response rate (ORR) increases to 40.4%, according to iRECIST, in TACTI-002 all-comer PD-L1 Phase II trial in 1st line non-small cell lung cancer (1L NSCLC) ORR improved across...
Immutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022
10. November 2022 09:00 ET
|
Immutep Limited
Media Release First activity evaluation of efti as part of triple combination therapy yields promising early results with 72.7% response rate and 90.9% disease control rate in 1st line NSCLC...
Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination
09. November 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference
04. November 2022 08:00 ET
|
Immutep Limited
Late-breaking abstract one of nine abstracts selected by SITC Communications Committee to be showcased at the SITC 2022 Press Conference Company to host Webcast on Thursday, 10th November...
Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
02. November 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company...
Immutep to Participate in Two Upcoming Investor Conferences
01. November 2022 19:59 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned
26. Oktober 2022 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Quarterly Activities Report
25. Oktober 2022 08:00 ET
|
Immutep Limited
Media Release Clinical development strategy for efti to prioritise non-small cell lung cancer (NSCLC), as well as advance head & neck squamous cell cancer (HNSCC) and metastatic breast cancer...
Immutep Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
05. Oktober 2022 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies...